Newport Medical Instruments Inc. has been acquired by Covidien plc
Newport Medical Instruments, Inc. (Newport), a manufacturer of ventilators for the portable, home care and critical care markets, has been acquired by Covidien plc. for US$108 million.
Newport is a physician-led company, focused on the design and manufacture of dependable ventilators that are affordable for caregivers worldwide.
Covidien plc. is a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices. Covidien creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
Oaklins' team in Los Angeles was engaged by the shareholders of Newport to pursue a sale of the business.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Eduard Bagdasarian
Oaklins Intrepid
Steven Davis
Oaklins Intrepid
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreClinical Partners has raised new debt facilities
Clinical Partners Ltd. has successfully restructured and upsized its debt facilities to better reflect the scale of the business. The company increased its original US$9.4 million facility, comprising a US$3.4 million term loan and a US$6 million revolving credit facility (RCF), to a US$27 million RCF.
Learn more